1Siskind, D, McCartney, L, Goldschlager, R, Kisely, S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–92.
2Cho, J, Hayes, RD, Jewell, A, Kadra, G, Shetty, H, MacCabe, JH, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 2018; 139: 237–47.
3Kesserwani, J, Kadra, G, Downs, J, Shetty, H, MacCabe, JH, Taylor, D, et al. Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. J Psychopharmacol 2019; 33: 449–58.
4Wimberley, T, MacCabe, JH, Laursen, TM, Sørensen, HJ, Astrup, A, Horsdal, HT, et al. Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 2017; 174: 990–8.
5Hayes, RD, Downs, J, Chang, CK, Jackson, RG, Shetty, H, Broadbent, M, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2015; 41: 644–55.
6Hayes, JF, Marston, L, Walters, K, King, MB, Osborn, DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry 2017; 211: 175–81.
7Vermeulen, JM, Van Rooijen, G, Van De Kerkhof, MPJ, Sutterland, AL, Correll, CU, De Haan, L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. Schizophr Bull 2019; 45: 315–29.
8Chou, FHC, Tsai, KY, Chou, YM. The incidence and all-cause mortality of pneumonia in patients with schizophrenia: a nine-year follow-up study. J Psychiatr Res 2013; 47: 460–6.
9Seminog, OO, Goldacre, MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax 2013; 68: 171–6.
10Shen, TC, Chen, CH, Huang, YJ, Lin, CL, Chang, TC, Tu, CY, et al. Risk of pleural empyema in patients with schizophrenia: a nationwide propensity-matched cohort study in Taiwan. BMJ Open 2018; 8(7): e021187.
11John, A, McGregor, J, Jones, I, Lee, SC, Walters, JTR, Owen, MJ, et al. Premature mortality among people with severe mental illness: new evidence from linked primary care data. Schizophr Res 2018; 199: 154–62.
12Gurillo, P, Jauhar, S, Murray, RM, MacCabe, JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2015; 2: 718–25.
13Haddad, PM. Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia. Evid Based Ment Health 2013; 16(4): 109.
14Kuo, C-J, Yang, S-Y, Liao, Y-T, Chen, WJ, Lee, W-C, Shau, W-Y, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39: 648–57.
15Stoecker, ZR, George, WT, O'Brien, JB, Jancik, J, Colon, E, Rasimas, JJ. Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: a retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months. Int Clin Psychopharmacol 2017; 32: 155–60.
16De Leon, J, Sanz, EJ, De las Cuevas, C. Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 2020; 46: 1–3.
17Liu, NH, Daumit, GL, Dua, T, Aquila, R, Charlson, F, Cuijpers, P, et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry 2017; 16: 30–40.
18Gurrera, RJ, Perry, NL. Clozapine-associated aspiration pneumonia: case series and review of the literature: reply. Psychosomatics 2019; 60: 103.
19Li, XH, Zhong, XM, Lu, L, Zheng, W, Wang, SB, Rao, WW, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med 2020; 50: 583–94.
20Ponsford, M, Castle, D, Tahir, T, Robinson, R, Wade, W, Steven, R, et al. Clozapine is associated with secondary antibody deficiency. Br J Psychiatry 2019; 214: 83–9.
21Siskind, D, Honer, WG, Clark, S, Correll, CU, Hasan, A, Howes, O, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci 2020; 45: 222–3.
22Stewart, R, Soremekun, M, Perera, G, Broadbent, M, Callard, F, Denis, M, et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 2009; 9: 51.
24Liu, K, Chen, Y, Lin, R, Han, K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020; 80(6): e14–8.
26Luykx, JJ, van Veen, SMP, Risselada, A, Naarding, P, Tijdink, JK, Vinkers, C. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry [Epub ahead of print] 4 May 2020. Available from: https://doi.org/10.1192/bjp.2020.92.